Resultados de búsqueda - Haiyi Guo

  • Mostrando 1 - 12 Resultados de 12
Limitar resultados
  1. 1
    YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor‐2 tyrosine kinase with potent activity <i>in vitro</i> and <i>in vivo</i>

    YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor‐2 tyrosine kinase with potent activity <i>in vitro</i> and <i>in vivo</i> por Shu Tian, Haitian Quan, Chengying Xie, Haiyi Guo, Fangfang Lü, Yongping Xu, Jin Li, Liguang Lou

    Publicado 2011
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  2. 2
    A phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: Armed oncolytic adenovirus for the treatment of head and neck cancers

    A phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: Armed oncolytic adenovirus for the treatment of head and neck cancers por Jianhua Chang, Xiaoying Zhao, Xianghua Wu, Ye Guo, Haiyi Guo, Junnin Cao, Yong Guo, Delun Lou, Dechao Yu, Jin Li

    Publicado 2009
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  3. 3
    PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib

    PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib por Leiping Wang, Qunling Zhang, Jian Zhang, Si Sun, Haiyi Guo, Zhen Jia, Biyun Wang, Zhimin Shao, Zhonghua Wang, Xichun Hu

    Publicado 2011
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  4. 4
    Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies

    Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies por Li Jin, Xinmin Zhao, Lei Chen, Haiyi Guo, Fangfang Lv, Jia Ka, Ke Yv, Feng‐Qing Wang, Chuan Li, Jun Qian, Chunlei Zheng, Yunxia Zuo

    Publicado 2010
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  5. 5
    Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study

    Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study por Wei Xu, Shenmiao Yang, Keshu Zhou, Ling Pan, Zengjun Li, Jianfeng Zhou, Sujun Gao, Daobin Zhou, Jianda Hu, Ru Feng, Haiwen Huang, Meng Ji, Haiyi Guo, Jane Huang, William Novotny, Shibao Feng, Jianyong Li

    Publicado 2020
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  6. 6
    Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma

    Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma por Haiyan Yang, Bing Xiang, Yuqin Song, Huilai Zhang, Weili Zhao, Dehui Zou, Fangfang Lv, Wei Guo, Aichun Liu, Caixia Li, Ziwen Tan, Yang Liu, Lina Fu, Haiyi Guo, William Novotny, Jane Huang, Yufu Li

    Publicado 2021
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  7. 7
    Combination Treatment with Sonrotoclax (BGB-11417), a Second-Generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor, Is Well Tolerated and Achieves Deep Responses in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN-CLL/SLL): Data from an Ongoing Phase 1/2 Study

    Combination Treatment with Sonrotoclax (BGB-11417), a Second-Generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor, Is Well Tolerated and Achieves D... por Constantine S. Tam, Mary Ann Anderson, Masa Lasica, Emma Verner, Stephen Opat, Shuo Ma, Robert Weinkove, Raúl Córdoba, Jacob D. Soumerai, Paolo Ghia, Sophie Leitch, James Hilger, Yiqian Fang, David Simpson, Haiyi Guo, Chan Y. Cheah

    Publicado 2023
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  8. 8
    Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study

    Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study por Yuqin Song, Quanli Gao, Huilai Zhang, Lei Fan, Jianfeng Zhou, Dehui Zou, Wei Li, Haiyan Yang, Ting Liu, Quanshun Wang, Fangfang Lv, Haiyi Guo, Liudi Yang, Rebecca Elstrom, Jane Huang, William Novotny, Vivian Wei, Jun Zhu

    Publicado 2019
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  9. 9
    Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase

    Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase por Yuqin Song, Keshu Zhou, Dehui Zou, Jianfeng Zhou, Jianda Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Haiyi Guo, Lei Zhou, Rebecca Elstrom, Jane Huang, William Novotny, Rachel Wei, Jun Zhu

    Publicado 2020
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  10. 10
    Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study

    Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study por Yuqin Song, Keshu Zhou, Dehui Zou, Jianfeng Zhou, Jianda Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Haiyi Guo, Lei Zhou, Jane Huang, William Novotny, Pil Kim, Yiling Yu, Binghao Wu, Jun Zhu

    Publicado 2022
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  11. 11
    Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis

    Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis por Yuqin Song, Quanli Gao, Huilai Zhang, Lei Fan, Jianfeng Zhou, Dehui Zou, Wei Li, Haiyan Yang, Ting Liu, Quanshun Wang, Fangfang Lv, Haiyi Guo, Xia Zhao, Dan Wang, Pei Zhang, Yidi Wang, Lei Wang, Tengfei Liu, Yun Zhang, Zhirong Shen, Jane Huang, Jun Zhu

    Publicado 2021
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  12. 12
    Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies

    Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies por Constantine S. Tam, Meletios Α. Dimopoulos, Ramón García‐Sánz, Judith Trotman, Stephen Opat, Andrew W. Roberts, Roger G. Owen, Yuqin Song, Wei Xu, Jun Zhu, Jianyong Li, Lugui Qiu, Shirley D’Sa, Wojciech Jurczak, Gavin Cull, Paula Marlton, David Gottlieb, Javier Muñoz, Tycel Phillips, Chenmu Du, Meng Ji, Lei Zhou, Haiyi Guo, Hongjie Zhu, Wai‐Yee Chan, Aileen Cohen, William Novotny, Jane Huang, Alessandra Tedeschi

    Publicado 2021
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:

Herramientas de búsqueda: